



COPY OF PAPERS
ORIGINALLY FILED

16NS X
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In Re Application of: JEON, et al.

APR 15 2002

Application No.: 09/722,776

Examiner: Fields, I.

TECH CENTER 1600/2900

Date Filed: November 27, 2000

Group Art Unit: 1645

For: NOVEL ENDONUCLEASE OF IMMUNE CELL, PROCESS FOR PRODUCING
THE SAME AND IMMUNE ADJUVANT USING THE SAME

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service
as First Class mail in an envelope addressed to the Commissioner for Patents,
Washington, D.C. 20231, on 3/28/02.

M. O. M. Reg. No. 40,764

Box: Fee

TRANSMITTAL LETTER

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Please find enclosed for filing the following:

- Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures and Preliminary Amendment;
- Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- Clean copy of amended pages;
- Marked-Up Version To Show Changes;
- Sequence listing (paper copy and computer readable form on floppy disk);
- Statement as required under 37 C.F.R. 1.821(f);
- Request for retroactive extension of time;
- Fee in the amount of \$55.00; and
- 1 postcard.

Please charge any underpayment or credit any overpayment to Deposit Account No. 50-0951. This transmittal letter is submitted in duplicate.

Respectfully submitted,

Dated: 3/28/02

Attorney Docket No. 9250-2



Robert J. Sacco
Registration No. 35,667
Mark D. Passler
Registration No. 40,764
Akerman, Senterfitt & Eidson, P.A.
222 Lakeview Avenue, Suite 400
P.O. Box 3188
West Palm Beach, FL 33402-3188
Tel: 561-653-5000



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/722,776	11/27/2000	Joong Yeong Jeon	9250-2	4908

7590 01/28/2002
ROBERT J. SACCO
Akerman, Senterfitt & Eidson, P.A.
222 Lakeview Avenue - 4th Floor
P.O. Box 3188
West Palm Beach, FL 33402-3188



[REDACTED] EXAMINER

FIELDS,IESHA P

[REDACTED] ART UNIT [REDACTED] PAPER NUMBER

1645

DATE MAILED: 01/28/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

APR 15 2002

TECH CENTER 1600/2900

FEB - 5 2002

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

FILE NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.



EXAMINER	
ART UNIT	PAPER NUMBER

DATE MAILED:

COPY OF PAPERS
ORIGINALY FILED

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN ONE EXTENDIBLE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to [redacted] whose telephone number is (703) 30 [redacted]

RECEIVED

APR 15 2002

TECH CENTER 1600/2900

Application N.: 09/722,775

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: _____

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE